



February 28, 2013

Gene Techno Science Co.,Ltd.
Code: 4584 (TSE Mothers)
President
Masanari Kawaminami

Issuance of 1st Series of Convertible Bonds and 2nd Series of Stock Options, and Extraordinary Meeting of Shareholders

The Board of Directors of Gene Techno Science Co.,Ltd. approved a resolution on February 28, 2013 to issue the 1st series of convertible bonds and the 2nd series of stock options for sale through a private placement. In addition, the directors approved a resolution to submit proposals for the issuance of these convertible bonds and stock options and for the election of two directors and two corporate auditors at the extraordinary meeting of shareholders to be held on April 26, 2013.

1. Overview of fund procurement

(1) Amount of funds to be raised

Issuance of the 1 st series of convertible bonds	1,200,000,000 yen
Issuance of the 2 nd series of stock options	15,040,000 yen
Exercise of the 2 nd series of stock options	1,599,966,720 yen
Total	2,815,006,720 yen

Note: Regarding the terms and conditions of issuance, please refer to the press release (Japanese version) disclosed on the same day.

(2) Use of proceeds

Proceeds will be used for the development of PEG-filgrastim and other biosimilars.

2. Profile of the intended allottee

(1) Name	Whiz Healthcare PE Fund Series 1 Investment Limited Partnership
(2) Address	36 th floor, Atago Green Hills Mori Tower 2-5-1, Atago, Minato-ku, Tokyo
(3) Activities	Japan and other industrialized countries must take actions in response to aging populations, growing healthcare expenditures, and the need to treat cancer and other intractable diseases. This partnership was established for the purpose of investing in companies that use creative scientific discoveries and innovative technologies to develop pharmaceuticals that can enable people to lead longer and healthier lives.
(4) Established	April 28, 2011
(5) Total capitalization	5,320 million yen
(6) General partner	Whiz Partners Inc. (URL: http://www.whizp.com)

3. Purpose and reason of fund procurement

Whiz Partners Inc., the intended allottee, is one of the few investment companies in Japan with a long history of successful investments in the bio-venture field since the emergence of this sector. Gene Techno Science plans to grow by developing new biopharmaceuticals while using biosimilars to establish a framework for consistent sales and earnings. This goal is consistent with the Whiz Partners investment strategy of supplying the funds that Japanese biotechnology start-up companies need to succeed. In addition, Gene Techno Science is a small company because of its fables operating structure. As a result, Gene Techno Science believes that significant synergies can be produced by utilizing the expansive business network that Whiz Partners has assembled over many years and the personnel that Whiz Partners can assign to work at Gene Techno Science. Both Gene Techno Science and Whiz Partners expect that the new business strategy that they have agreed upon will lead to maximizing Gene Techno Science shareholder value.

4. Extraordinary meeting of shareholders

The directors of Gene Techno Science have approved a resolution to hold an extraordinary meeting of shareholders as follows. At this meeting, shareholders will be asked to approve proposals to conduct this private placement of convertible bonds and stock options and to elect two Whiz Partners executives as outside directors.

- (1) Date: Friday, April 26, 2013 at 10:00 a.m.
- (2) Location: 3rd floor, Bellesalle Yaesu, Yaesu First Financial Building
1-3-7, Yaesu, Chuo-ku, Tokyo
- (3) Agenda of the meeting:
 - Proposals to be resolved
 - 1st Agenda: Issuance of the 1st series of convertible bonds and the 2nd series of stock options through a private placement
 - 2nd Agenda: Election of two (2) directors
 - 3rd Agenda: Election of two (2) corporate auditors

Media Contact

Eisaku Nakamura
Business Development Dept.
Tel: (81)-3-3517-1353
E-mail: info@g-gts.com